AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A phosphatidyl-L-serine <u>sodium salt productcomposition</u> having a fatty acid composition identical to that of soybean lecithin and a degree of peroxidation of less than 5 produced by reacting <u>a-phosphatides</u> of formula (II):

$$R - O - PO(OH) - O - R_2$$
 (II)

wherein R is diacylglycerol and R₂ is CH₂ – CH₂ – NH₂ or CH₂ – CH₂ – N(CH₃)₃, with serine-a primary or secondary alcohol with a chain length of between C2 to C4, optionally substituted with one or more polar groups selected from the group consisting of amino, hydroxy and carboxy, in a single aqueous phase in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a *Streptomyces hachijoense* strain to catalyze the reaction, and wherein said phosphatides of formula II are obtained from soybean, wherein said phospholipase D is purified by eluting on an anionic cationic exchange resin at a pH of 6.2.

2. **(Currently Amended)** The A phosphatidyl-L-serine sodium salt product composition having a fatty acid composition identical to that of egg lecithin and a degree of peroxidation of less than 5 produced by reacting a phosphatides of formula (II):

$$R - O - PO(OH) - O - R_2$$
 (II)

wherein R is diacylglycerol and R₂ is CH₂ – CH₂ – NH₂ or CH₂ – CH₂ – N(CH₃)₃, with <u>serine at primary or secondary alcohol with a chain length of between C2 to C4, optionally substituted with one or more polar groups selected from the group consisting of amino, hydroxy and carboxy, in a single aqueous phase in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a *Streptomyces hachijoense* strain to catalyze the reaction, and wherein said phosphatides of formula II are obtained from egg, wherein said phospholipase D is purified by eluting on an anionic cationic exchange resin at a pH of 6.2.</u>

3. (Currently Amended) A phosphatidyl-L-serine <u>sodium salt productcomposition</u> having a fatty acid composition identical to that of soybean lecithin and a degree of peroxidation of less than 5 produced by reacting <u>a-phosphatides</u> of formula (II):

$$R - O - PO(OH) - O - R_2$$
 (II)

wherein R is diacylglycerol and R₂ is CH₂ – CH₂ – NH₂ or CH₂ – CH₂ – N(CH₃)₃, with <u>serine a primary or secondary alcohol with a chain length of between C2 to C4, optionally substituted with one or more polar groups selected from the group consisting of amino, hydroxy and carboxy, in a <u>single aqueous phase</u> in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a *Streptomyces hachijoense* strain to catalyze the reaction, and wherein said phosphatides of formula II are obtained from soybean and wherein said phospholipase D is purified by eluting on an anionic cationic exchange resin at a pH of 6.2.</u>

4. **(Currently Amended)** A phosphatidyl-L-serine <u>sodium salt productcomposition</u> having a fatty acid composition identical to that of egg lecithin and a degree of peroxidation of less than 5 produced by reacting a-phosphatides of formula (II):

$$R - O - PO(OH) - O - R_2$$
 (II)

wherein R is diacylglycerol and R₂ is CH₂ – CH₂ – NH₂ or CH₂ – CH₂ – N(CH₃)₃, with <u>serine a primary or secondary alcohol with a chain length of between C2 to C4, optionally substituted with one or more polar groups selected from the group consisting of amino, hydroxy and carboxy, in a <u>single aqueous phase</u> in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a *Streptomyces hachijoense* strain to catalyze the reaction and wherein said phosphatides of formula II are obtained from soybean and wherein said phospholipase D is purified by eluting on an anionic cationic exchange resin at a pH of 6.2.</u>

5. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a phosphatide-phosphatidyl-L-serine sodium salt of formula (I)

$$R - O - PO(OH) - O - R_1$$
 (I)

wherein R is diacylglycerol and R₁ is an hydroxyl group,

made by the process of reacting a phosphatide of formula (II):

$$R - O - PO(OH) - O - R_2$$
 (II)

wherein R is diacylglycerol and R_2 is $CH_2 - CH_2 - NH_2$ or $CH_2 - CH_2 - N(CH_3)_3$, with-<u>serine a primary or secondary alcohol with a chain length of between C2 to C4, optionally substituted with one or more polar groups selected from the group consisting of amino, hydroxy and carboxy, in a single aqueous phase in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a *Streptomyces hachijoense* strain to catalyze the reaction to obtain said phosphatide according to formula (I).</u>

6. **(Currently Amended)** A cosmetic composition comprising a pharmaceutically acceptable carrier and a phosphatide phosphatidyl-L-serine sodium salt-of formula (I)

$$R - O - PO(OH) - O - R_1$$
 (I)

wherein R is diacylglycerol and R₁ is an hydroxyl group,

made by the process of reacting a phosphatide of formula (II):

$$R - O - PO(OH) - O - R_2$$
 (II)

wherein R is diacylglycerol and R_2 is $CH_2 - CH_2 - NH_2$ or $CH_2 - CH_2 - N(CH_3)_3$, with <u>serine a</u> primary or secondary alcohol with a chain length of between C2 to C4, optionally substituted with

one or more polar groups selected from the group consisting of amino, hydroxy and carboxy, in a single aqueous phase in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a *Streptomyces hachijoense* strain to catalyze the reaction to obtain said phosphatide according to formula (I).

7. (Currently Amended) A food and dietary supplement comprising a carrier and a <u>phosphatidyl-L-serine sodium salt phosphatide</u>_of formula (I)

$$R - O - PO(OH) - O - R_1$$
 (I)

wherein R is diacylglycerol and R_1 is an hydroxyl group,

made by the process of reacting a phosphatide of formula (II):

$$R - O - PO(OH) - O - R_2$$
 (II)

wherein R is diacylglycerol and R_2 is $CH_2 - CH_2 - NH_2$ or $CH_2 - CH_2 - N(CH_3)_3$, with-<u>serine a primary or secondary alcohol with a chain length of between C2 to C4, optionally substituted with one or more polar groups selected from the group consisting of amino, hydroxy and carboxy, in a single aqueous phase in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a *Streptomyces hachijoense* strain to catalyze the reaction to obtain said phosphatide according to formula (I).</u>

- 8. (Currently Amended) The food and dietary supplement according to claim 7, wherein the phosphatide according to formula (I) is phospatidyl-L-serine and wherein the Streptomyces hachijoense strain used to catalyze the reaction is ATCC 19769.
- 9. (Currently Amended) A pharmaceutical composition capable of being administered orally comprising a pharmaceutically acceptable carrier and the phosphatidyl-L-serine product composition according to claim 3 or 4.

- 10. (Currently Amended) A cosmetic composition for topical application to the skin comprising a pharmaceutically acceptable carrier and phosphatidyl-L-serine made by the process according to claim 3 or 4.
- 11. (Currently Amended) A food and dietary supplement capable of being administered orally comprising a carrier and phosphatidyl-L-serine made by the process-according to claim 3 or 4.
- 12. **(Original)** A method of treating psycho-physical stress, attention, concentration and memory deficits commonly associated with advancing age, comprising administering a therapeutically effective amount of a pharmaceutical composition according to claim 5.
- 13. (**Original**) A method of treating dermatitis or skin with impaired physiological functions comprising applying a cosmetic composition according to claim 6 to the skin.
- 14. **(Original)** A method of treating psycho-physical stress, attention, concentration and memory deficits commonly associated with advancing age comprising administering a food and dietary supplement according to claim 7.
- 15. (Currently Amended) The pharmaceutical composition according to claim 5 or 9 in the form of a capsule, tablet or granule.
- 16. (Currently Amended) The cosmetic composition according to claim 6 or 10 in the form of a cream or a gel.
- 17. (**Original**) A food and dietary supplement according to claim 7 in the form of a capsule, tablet or granule.
- 18. (Original) A food and dietary supplement according to claim 11 in the form of a capsule, tablet or granule.

- 19. (Original) The food and dietary supplement according to claim 8, wherein the phosphatide of formula (II) is selected from the group consisting of purified soybean lecithin and crude soybean lecithin.
- 20. (Currently Amended) The phosphatidyl-L-serine product composition according to claim 1 or 2, wherein the phosphatidyl-L-serine product composition is at least 95% pure.
- 21. (Currently Amended) The phosphatidyl-L-serine product composition according to claim 1 or 2, wherein the formula II phosphatide reactant is phosphatidylcholine, and wherein said phosphatidylcholine reactant is completely converted to product.